Announced Thu, 9 Jul · 09:16 IST
Semaglutide batches out of spec, supplies delayed
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-7.7%1-day move
₹1351.10
prior close
₹1335.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.1-1.6-0.2+0.9-7.7-8.5-7.8-9.0-9.3-9.6————
Up moveDown movePending
AI summary
Dr Reddys found certain batches of semaglutide out of specification due to an issue with the active pharmaceutical ingredient. Commercial supplies of the product will be delayed until the root cause is identified and fixed. The company says there is no impact on patient safety or on existing global regulatory filings. Management has scheduled a conference call today at 16:30 IST to discuss the matter and answer questions.
Likely market impact
Near-term revenue from semaglutide sales may take a hit due to supply delays. Investors should watch the management call for clarity on duration and financial impact.